4.6 Article

Treatment of Anastomotic Recurrence After Esophagectomy

Journal

ANNALS OF THORACIC SURGERY
Volume 114, Issue 2, Pages 418-425

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.athoracsur.2021.07.101

Keywords

-

Funding

  1. National Institutes of Health/National Cancer Institute Cancer Center Support [P30 CA008748]

Ask authors/readers for more resources

Isolated local recurrence after curative esophagectomy for esophageal cancer is a rare event. The risk factors for recurrence include advanced T stage, signet ring histology, and serious complications. Although complex surgical resection is required, in very select cases, more aggressive treatment may be warranted.
BACKGROUND Isolated local recurrence after curative esophagectomy for esophageal cancer is a rare event. Although it is potentially curable, management can be challenging.METHODS We retrospectively reviewed all patients undergoing esophagectomy for esophageal adenocarcinoma (EAC) from 2000 to 2019. Date of recurrence was defined as the date at which the initial abnormal surveillance study result or symptomatic presentation led to further workup and subsequent pathologic diagnosis of recurrence. Overall survival after recurrence was estimated using Kaplan-Meier methods and compared between treatment groups using the log -rank test.RESULTS Of the 1370 patients with EAC who underwent esophagectomy in our cohort, 531 (39%) developed recur-rence of their disease. The 5-year cumulative incidence of recurrence was 2.7% (95% CI, 2.0%-3.6%) for local, 6.3% (95% CI, 5.2%-7.8%) for regional, and 22.0% (95% CI, 20.0%-24.4%) for distant recurrences. On univariable and multivariable competing-risk regression analysis, advanced pT stage, signet ring histology, and serious complication were independently associated with local recurrence. Patients with local recurrence treated with definitive therapy had a median survival after recurrence of 19.1 months (95% CI, 11.4-33.2 months) compared with 10.6 months (95% CI, 8.5-14.2 months) for chemotherapy or radiotherapy alone and 1.73 months (95% CI, 0.23-15.6 months) for no treatment (P < .001).CONCLUSIONS Isolated local recurrence occurred in only 3% of patients. Advanced T stage, signet cell histology, and serious complication were risk factors for recurrence. Although complex surgical resection is required, in very select cases, more aggressive treatment may be warranted.(Ann Thorac Surg 2022;114:418-25)(c) 2022 by The Society of Thoracic Surgeons

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available